Siemens Healthiness Nearing Fiscal Year 2024 Goals Following Strong Second Quarter Performance

Quarter 2 of Fiscal Year 2024:

  • The equipment book-to-bill ratio stands at a commendable 1.08.
  • Comparable revenue growth is at 3.0%, excluding rapid COVID-19 antigen tests, showing a strong performance compared to the previous year’s quarter (which had a growth of 11.7%).
  • Imaging revenue growth is at 2.6%, with an adjusted EBIT margin of 20.2%.
  • Diagnostics revenue growth is at 3.7%, excluding rapid COVID-19 antigen tests at 4.1%, with an adjusted EBIT margin of 4.1%, significantly higher than the previous year.
  • Varian revenue experiences a slight decline of 2.1% compared to the exceptional growth of 27% in the prior-year quarter, yet there’s a clear enhancement in the adjusted EBIT margin to 16.4%.
  • Advanced Therapies see a notable growth of 8.0% against strong growth in the previous year, with an adjusted EBIT margin of 16.2%.
  • Overall adjusted EBIT margin stands at 15.1%.
  • Adjusted basic earnings per share are at €0.55.

Outlook for Fiscal Year 2024:

  • Siemens Healthiness confirms the expectation of comparable revenue growth between 4.5% and 6.5% (excluding revenue from rapid COVID-19 antigen tests, between 5.0% and 7.0%) and adjusted basic earnings per share between €2.10 and €2.30.

Bernd Montag, CEO of Siemens Healthiness AG, states: “The Healthineers team has continued its successful growth trajectory, even relative to an excellent prior-year quarter. After an overall strong first half of the year, we are once again well on our way to achieving our targets for the financial year.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter